908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

908 Devices reports revenue growth, eyes biopharma sector improvement

908 Devices showed solid financial performance in 2022, with revenue growth and strategic expansions.
While facing challenges like macro headwinds and lower REBEL placements, the company is focused on innovation.
Opportunities lie in biopharma sector improvement, product utilization rates, and unit growth expectations.
Maintaining a strong cash position and disciplined capital deployment are key strengths for future growth.

908 Devices reports revenue growth and strategic partnerships driving innovation

908 Devices delivered solid performance in Q1 2023, marked by revenue growth, strong recurring revenue, and strategic partnerships driving innovation and market expansion.
While facing challenges in operating expenses and gross margins, the company's focus on handheld devices, recurring revenues, and cost management positions it for future success.
With a robust cash position, ongoing product launches, and a diverse sales funnel, 908 Devices is poised to capitalize on opportunities in the biopharma and cell therapy markets.

908 Devices reports revenue growth and strategic focus for growth

908 Devices showcased revenue growth and strong performance in key product segments. While managing expenses prudently and focusing on key markets, the company faces challenges with a net loss and the need for additional handheld unit growth. Opportunities lie in upcoming product launches, government contracts, and pipeline updates.

908 Devices reports Q3 revenue growth, eyes strong 2024 prospects

908 Devices showed solid performance in Q3 2023, driven by growth in handheld devices and strategic collaborations. Despite challenges in the bio-processing space, the company remains optimistic about future growth and product development.
With a strong cash position, no debt, and a focus on returning to high growth rates, 908 Devices is poised for success in 2024. The company's emphasis on process analytical technology tools and expanding market offerings presents promising opportunities for the future.
While facing challenges in revenue expectations and utilization rates, 908 Devices is actively addressing these issues to drive sustainable growth. The company's commitment to innovation and market expansion positions them well for long-term success.

908 Devices reports strong Q4 performance and optimistic outlook for 2024

908 Devices showed revenue growth and improved net loss in Q4 2023, with a positive outlook for 2024.
The company's strong cash position, successful partnerships, and product confidence are key strengths.
Challenges include margin pressures from pricing adjustments and increased spending.
Opportunities lie in revenue growth guidance, customer interest in new products, and market expansion plans.

908 Devices reports solid Q1 performance, eyes growth opportunities

908 Devices had a strong start in Q1 2024, driven by revenue growth and RedWave acquisition.
Challenges include net loss, declining desktop product revenue, and cost management.
Opportunities lie in engagement with cell therapy accounts, revenue synergies, and cash flow improvement.
Strategic fit of RedWave acquisition offers growth potential and cost synergies in the long term.

908 Devices reports solid Q2 earnings, eyes growth through diversification

908 Devices demonstrated strong revenue growth in Q2 2024, driven by robust performance in handheld forensics devices.
While facing challenges in desktop product revenue, the company's focus on recurring revenue and market expansion bodes well for future prospects.
Strategic adjustments and continued emphasis on operational excellence position 908 Devices for sustained success in diverse markets.

908 Devices faces revenue challenges but pursues growth opportunities

908 Devices reported mixed financial performance in Q3 2024, with revenue growth but falling short of expectations, leading to a net loss.
The company is taking steps to optimize operations, identify growth drivers, and drive margin expansion for future success.
Challenges include revenue guidance adjustments, competitive pressures, and financial losses, which require strategic responses.
Opportunities lie in product innovation, strategic partnerships, and effective implementation of sales strategies to drive growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne

MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products, will pair its Maurice icIEF separation instrument with 908 Devices ZipChip device to deliver a seamless workflow for deeper protein characterization.

Bio-Techne and 908 Devices Announce Joint Collaboration

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products, will pair its Maurice icIEF separation instrumen

908 Devices and Bio-Techne Announce Joint Collaboration

BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2021 before market open on Thursday, May 13, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices to Report First Quarter Financial Results on May 13, 2021 and Host 2021 Annual Meeting of Stockholders on June 17, 2021

BOSTON--(BUSINESS WIRE)--Experienced HR executive with global tech background joins executive leadership team

908 Devices Appoints Michele Fournier as Chief People Officer

BOSTON--(BUSINESS WIRE)--Agency selected the MX908 to work closely with local law enforcement to prevent drug smuggling as opioid crisis rages across the country.

908 Devices Provides Handheld Mass Spec for Trace Detection to U.S. Border Patrol

908 Devices has seen a soft first quarter as a publicly traded company. This quarter was accompanied by a softer guidance for 2021 as well, despite a big army contract.

908 Devices - Mass Spectrometry, Not For The Masses

908 Devices expects 45% revenue growth this year. About 8% below its IPO price, MASS could be a good bet.

908 Devices Reports 50% Top Line Growth, Guides 2021 Up 45%

908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to the current visibility. The 908 Devices Analyst: SV Leerin analyst Puneet Souda has reiterated the $70 price target and maintained his outperform rating on the stock.

Cathie Wood Is Bullish On 908 Devices. An Analyst Makes A Case For The Stock

908 Devices' (MASS) CEO Kevin Knopp on Q4 2020 Results - Earnings Call Transcript

2020 Revenue Increased 50% Over Prior Year 2020 Revenue Increased 50% Over Prior Year

908 Devices Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Revenue Outlook

Multi-mission device will support field teams with trace detection point of need analysis Multi-mission device will support field teams with trace detection point of need analysis

908 Devices Awarded Multi-Year $25M Purchase Order to Enable the U.S. Army

American Well Corporation

Athira Pharma

Broadstone Net Lease

COMPASS Pathways

Coupang

Dyne Therapeutics

GreenBox POS

Metacrine

Outset Medical

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

Bolt Biotherapeutics

Midwest Holding

NexImmune

Ortho Clinical Diagnostics Holdings

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week

Amneal Pharmaceuticals

BOSTON--(BUSINESS WIRE)--Company adds two directors with financial, pharmaceutical, and consumable business expertise.

908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year of 2020 before market open on Tuesday, March 30, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” secti

908 Devices to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021

BOSTON--(BUSINESS WIRE)--Bioprocess Veteran Steve Davenport joins company as Vice President of Commercial Sales.

908 Devices Strengthens Commercial Team with Addition of New Vice President

BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the closing of its upsized initial public offering of shares of its common stock, with 7,475,000 shares offered and sold by the Company at a public offering price of $20.00 per share, which includes the full exercise of the underwriters' option to purchase an additional 975,000 shares of common stock from the Company. The shares beg

908 Devices Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

908 Devices is a very interesting business with great potential and recent operating momentum. Expectations have risen quite a bit after a big opening day move higher; I still like the long-term potential.

908 Devices: Very Interesting Offering

Shares of 908 Devices Inc. more than doubled on their public debut, as the Massachusetts-based biochemical analysis device company's stock opened 127.6% above the upsized initial public offering's price. The company sold 6.5 million shares at an IPO price of $20.00 a share to raise $130 million, up from plans to offer 6.25 million shares earlier this week.

908 Devices stock more than doubles on its public debut

Research device maker prices shares at $20 each.

908 Devices Raises $130 Million in What May Be the Last IPO of 2020

BOSTON--(BUSINESS WIRE)--908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial public offering of shares of its common stock, with 6,500,000 shares being offered by the Company at a public offering price of $20.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 975,000 shares of common stock from the Company at the pu

News for 908 Devices Stock (MASS)